{"id":"gls-010","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4297856","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, GLS-010 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"GLS-010 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:00.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05688215","phase":"PHASE1, PHASE2","title":"Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2023-03-07","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma","enrollment":56},{"nctId":"NCT06055738","phase":"PHASE2","title":"Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2023-10-09","conditions":"Locally Advanced Cervical Cancer","enrollment":20},{"nctId":"NCT06009029","phase":"PHASE2","title":"SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-08","conditions":"Locally Advanced Pancreatic Cancer","enrollment":96},{"nctId":"NCT05978401","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2023-08-10","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":152},{"nctId":"NCT05909436","phase":"PHASE1, PHASE2","title":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","status":"RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2022-10-31","conditions":"Solid Tumor","enrollment":107},{"nctId":"NCT05900765","phase":"PHASE2","title":"A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-06-14","conditions":"Classical Hodgkin Lymphoma","enrollment":54},{"nctId":"NCT03713905","phase":"PHASE1","title":"Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2017-07-01","conditions":"Advanced Solid Tumors","enrollment":293},{"nctId":"NCT05798819","phase":"PHASE3","title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2023-05-01","conditions":"Persistent, Recurrent, or Metastatic Cervical Cancer","enrollment":424},{"nctId":"NCT05540483","phase":"NA","title":"RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-08-01","conditions":"Biliary Carcinoma","enrollment":31},{"nctId":"NCT05518318","phase":"PHASE3","title":"GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)","status":"UNKNOWN","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2022-09","conditions":"Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":60},{"nctId":"NCT05221775","phase":"PHASE1","title":"Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-11-01","conditions":"First-line Treatment, Advanced Gastric Carcinoma","enrollment":18},{"nctId":"NCT03655483","phase":"PHASE2","title":"Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2018-08-24","conditions":"Classical Hodgkin's Lymphoma","enrollment":85},{"nctId":"NCT03972722","phase":"PHASE2","title":"Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer","status":"UNKNOWN","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2019-05-15","conditions":"Cervical Cancer","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant Human Anti-PD-1 Monoclonal Antibody","Full-human anti-pd-1 monoclonal antibodies","GLS-010 therapy"],"phase":"phase_3","status":"active","brandName":"GLS-010","genericName":"GLS-010","companyName":"Guangzhou Gloria Biosciences Co., Ltd.","companyId":"guangzhou-gloria-biosciences-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GLS-010 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}